BIO 2026: Making biotech IPOs great again and the forgotten pharma antitrust review

Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.